{
    "clinical_study": {
        "@rank": "110825", 
        "arm_group": [
            {
                "arm_group_label": "A, CIK", 
                "arm_group_type": "Experimental", 
                "description": "Biological/Vaccine:   Cytokine-Induced Killer Cells"
            }, 
            {
                "arm_group_label": "B, CONTROL", 
                "arm_group_type": "No Intervention", 
                "description": "Regular follow up with no intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized controlled study. About 200 patients with hepatocellular carcinoma who\n      underwent radical resection will be included. The patients will be randomized to group A\n      (receive CIK treatment) or group B (just regularly follow up) without any anti-cancer\n      treatment after resection of HCC, and the randomize ratio will be 1:1."
        }, 
        "brief_title": "CIK Treatment for HCC Patient Underwent Radical Resection", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Hepatocellular", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients over 18 years of age.\n\n          -  Without any prior anti-cancer therapy.\n\n          -  Patients who have a life expectancy of at least 12 weeks.\n\n          -  Patients already had radical resection of HCC.\n\n        Definition of radical resection in this study:\n\n          -  All tumors were moved out, with a clean resection margin.\n\n          -  Number of tumors less than 3.\n\n          -  Without tumor invasion of the main trunk and first branch of the portal vein, or\n             hepatic duct, or hepatic vein.\n\n          -  No hepatic hilum lymphnode metastasis.\n\n          -  No distance metastasis.\n\n          -  Hepatocellular carcinoma with histological diagnose.\n\n          -  No major post-operative complication.\n\n          -  Patients who have an performance status of 0, or 1.\n\n          -  Cirrhotic status of Child-Pugh class A only.\n\n          -  The following laboratory parameters:\n\n          -  Patients who give written informed consent.\n\n        Exclusion Criteria:\n\n          -  Previous or concurrent cancer that is distinct in primary site or histology from HCC.\n\n          -  History of cardiac disease.\n\n          -  Active clinically serious infections ( over grade 2 National Cancer Institute-Common\n             Terminology Criteria for Adverse Events  version 3.0)\n\n          -  Known history of human immunodeficiency virus (HIV) infection\n\n          -  Known Central Nervous System tumors including metastatic brain disease.\n\n          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior\n             to study entry.\n\n          -  History of organ allograft.\n\n          -  Known or suspected allergy to the investigational agent or any agent given in\n             association with this trial.\n\n          -  Pregnant or breast-feeding patients.\n\n          -  Any condition that is unstable or which could jeopardize the safety of the patient\n             and his/her compliance in the study.\n\n          -  Excluded therapies and medications, previous and concomitant:\n\n        Prior use of any anti-cancer treatment for HCC, eg. chemotherapy, radiotherapy. Antiviral\n        treatment is allowed."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01749865", 
            "org_study_id": "NCT00769106"
        }, 
        "intervention": {
            "arm_group_label": "A, CIK", 
            "description": "Cytokine-Induced Killer Cells treatment for 4 cycles", 
            "intervention_name": "Cytokine-Induced Killer Cells", 
            "intervention_type": "Biological", 
            "other_name": "CIK"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 12, 2012", 
        "location": {
            "contact": {
                "email": "daughsea@hotmail.com", 
                "last_name": "LI XU, M.D.", 
                "phone": "862087343582"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Immunotherapy"
            }, 
            "investigator": {
                "last_name": "LI XU, M.D.", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients With Hepatocellular Carcinoma Who Underwent Radical Resection", 
        "other_outcome": {
            "description": "To evaluate safety of CIK treatment as an adjuvant therapy in patients with hepatocellular carcinoma (HCC) who underwent radical resection.", 
            "measure": "Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sun Yat-sen University: China", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate efficacy of CIK treatment as an adjuvant therapy in patients with hepatocellular carcinoma (HCC) who underwent radical resection.", 
            "measure": "Time to recurrence", 
            "safety_issue": "No", 
            "time_frame": "5-year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01749865"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "LI Sheng-ping", 
            "investigator_title": "Vice director, Sun Yat-sen University Cancer Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Disease Free Survival", 
            "measure": "Disease Free Survival", 
            "safety_issue": "No", 
            "time_frame": "5 year"
        }, 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}